Beyond Air Announces Termination of the Loan and Security Agreements with Avenue Capital
September 27, 2024
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
September 27, 2024
Beyond Air to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
September 23, 2024
Beyond Air® Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
August 6, 2024
Beyond Air® Publishes Peer-Reviewed Journal Article in Scientific Reports with Clinical Data Showing Nitric Oxide was Safe and Beneficial Adjunct Therapy for Subjects with Viral Pneumonia
July 31, 2024
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
July 23, 2024
Beyond Air® To Participate in the BTIG Virtual Biotechnology Conference 2024
July 16, 2024
Beyond Air® Reports Fiscal Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
June 24, 2024
Beyond Air® Appoints David Webster as Chief Commercial Officer
June 13, 2024
Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO)
June 3, 2024

Sign up for updates from Beyond Air, Inc.

Unsubscribe from all email communications. Unsubscribe